Sanofi's Formulation Patents on Multibillion-Dollar Lantus(R) are Invalidated by U.S. Patent and Trademark Office via IPR, Announces Mylan

Mylan achieves key milestone to provide U.S. diabetes patients with more affordable generic version of Sanofi's Lantus® insulin glargine vials HERTFORDSHIRE, England and PITTSBURGH, Dec. 13, 2018 -- (Healthcare Sales & Marketing Network) -- Mylan N... Biopharmaceuticals, Generics, Endocrinology, Litigation Mylan, Sanofi, Lantus, insulin glargine, Lantus SoloSTAR
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news